PD(L)anner - March 2022

本レポート、PD(L)anner - March 2022(英語版)では、PD-(L)1阻害剤領域のニュース・分析についてのEvaluate Vantageをまとめています。特に、薬価の動向、中国市場などの最新情報もご紹介します。

The Evaluate Vantage PD(L)anner – March 2022 provides news, insights and analysis on the PD-(L)1 antibody landscape. Among other issues, we focus on potential pricing changes, provide an update on what’s happening in China and other markets, and share our views on the results of recent studies. 

To access your complimentary copy of this special report, please fill in this form.

.

REPORT HIGHLIGHTS

Pricing competition:
So far there has been almost no pricing competition in the US, despite a number of drugs being available on the market. This could soon start to shift, though, as potential new market entrants emerge.
China’s impact:
An attempt to secure FDA approval based on trial data entirely from China looks likely to end in failure. Does this preclude others from taking a serious step towards bigger changes in the market?
Recent studies:
Which studies have read out positively since the last report – and which have not? We discuss the key takeaways.
Thumbnail
Thumbnail